Skip to content

A multicenter, observational cohort study of Genome-wide association study based on whole-exome sequencing in childhood idiopathic nephrotic syndrome

A multicenter, observational cohort study of Genome-wide association study based on whole-exome sequencing in childhood idiopathic nephrotic syndrome

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032325
Enrollment
Unknown
Registered
2020-04-25
Start date
2018-09-01
Completion date
Unknown
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary nephrotic syndrome

Interventions

Case series:NA

Sponsors

Children's Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. An onset age from birth to 18 years; 2. A diagnosis of PNS according to the following criteria: (1) nephrotic proteinuria: proteinuria >=50mg/kg or morning urine protein/creatinine (mg/mmol) >=200.0 in 24hours, (2) hypoproteinaemia: serum albumin less than 25g/L; (3) hyperlipidaemia: serum cholesterol higher than 5.7mmol/L; (4) different degrees of oedema. (1) and (2) of the above four items are necessary for diagnosis. Patients with SSNS or FRNS/SDNS should respond to prednisone or prednisolone within 4 weeks,and FRNS/SDNS should also meet the standard of two consecutive relapses during the reduction of corticosteroid therapy or within 2 weeks of discontinuation of corticosteroid therapy and more than two relapses within a 6month period or relapse for more than 4 of 12 months during the course of the disease. Patients with SRNS exhibit persistent proteinuria despite that 60 mg / (m2*d) dose of prednisone is administered orally for 4 weeks, followed by a dose of 40 mg / m2 intermittently for 4 weeks according to the standard International Study of Kidney Disease in Children (ISKDC).

Exclusion criteria

Exclusion criteria: (1) Patients with chronic kidney disease(CKD)caused by factors such as congenital nephrotic syndrome or secondary nephrotic syndrome (allergic purpura, lupus, hepatitis B, diabetes, hereditary nephritis, severe infection, tumour and drugs); (2) Patients with a positive genetic test associated with podocytopathies.

Design outcomes

Primary

MeasureTime frame
WES;eGFR;

Secondary

MeasureTime frame
histopathological outcomes;

Countries

China

Contacts

Public ContactQiu Li

Department of Nephrology, Key Laboratory of the Ministry of Education, Children's Hospital of Chongqing Medical University

liqiu809@126.com+86 13896761809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026